u/Many_Easy_V2

As of about 5:30 PM ET: TLRY’s after-hours range is $4.48–$4.86.

$4.83 regular-session close.

“Medical cannabis is becoming an increasingly important part of modern medicine, and Germany is helping define what a responsible, physician-led market can look like.

Today's progress in Germany's medical cannabis framework is encouraging. Greater clarity for physicians is good for patients, good for the healthcare system and important for the continued development of medical cannabis as a legitimate therapeutic option.
This is meaningful progress and an important foundation for what comes next.

There is more work to be done to create the clarity, confidence and consistency that physicians and patients need for the long term.

But the direction is positive, and the opportunity ahead is significant.
At Tilray Brands, Inc., we have spent years investing ahead of that opportunity — building the science, infrastructure, cultivation, manufacturing, distribution and patient access capabilities needed to support the continued evolution of medical cannabis across Europe.

Today, we hold a leading position in Germany's medical cannabis oil market with 45% market share, operate cultivation and manufacturing capabilities in Germany and Portugal, and through CC Pharma GmbH reach approximately 16,000 pharmacies across Germany.
And we believe we are still at the beginning.

Germany has the opportunity to continue setting the standard for responsible, physician-led medical cannabis in Europe. We look forward to continuing to work alongside policymakers, physicians, regulators and healthcare partners to advance a framework that supports patients, empowers physicians and allows this market to reach its full potential.
Medical cannabis is part of the future of medicine. The progress we are seeing today gives us even greater confidence in what lies ahead.”

Canopy Growth (CGC) — July 26, 2016 — TSX — Opening Bell

Aurora Cannabis (ACB) — July 24, 2017 — TSX — Opening Bell

Canadian cannabis industry group — October 17, 2018 — TSX — Opening Bell (legalization day)

Scythian Biosciences — February 22, 2018 — Nasdaq — Closing Bell

Tilray (TLRY) — July 19, 2018 — Nasdaq — Closing Bell

FSD Pharma (HUGE) — March 6, 2020 — CSE — Opening Bell

Flora Growth (FLGC) — May 20, 2021 — Nasdaq — Closing Bell

Incannex Healthcare (IXHL) — February 25, 2022 — Nasdaq — Closing Bell

Leafly (LFLY) — April 20, 2022 — Nasdaq — Opening Bell

Canopy Growth (CGC) — December 12, 2022 — Nasdaq — Opening Bell

Tilray Brands (TLRY) — April 20, 2023 — Nasdaq — Closing Bell

Verano Holdings (VRNO) — October 18, 2023 — Cboe Canada — Opening Bell

Aurora Cannabis (ACB) — February 18, 2026 — Nasdaq — Closing Bell

AdvisorShares Pure US Cannabis ETF (MSOS) — August 10, 2026 — NYSE — Opening Bell

Trulieve (TCNNF) — August 18, 2026 — NYSE — Closing Bell

Did I miss any?

Upcoming cannabis catalysts relating to Tilray.

1. DEA rescheduling — post-hearing process underway; next major step is the ALJ recommendation.

2. Curaleaf–Aurora — takeover bid could spark broader cannabis M&A.

3. Hemp/THC legislation — could significantly affect hemp-derived THC products and beverages.

4. European medical cannabis — continued growth/regulatory developments, especially Germany.

5. More M&A — Aurora/Curaleaf could encourage consolidation across the sector.

6. Q1 ending August 31st and next earnings call ~ October 8, 2026.

7. Midterm elections November 3, 2026.

8. Unanticipated surprises, rumours, and disappointments.

For Tilray: DEA + M&A + hemp legislation are probably the three biggest catalysts.

The Dales Report (“TDR”) isn’t just a media company making money from readers or advertising. They can be categorized as “pay for play” and/or entertainment.

Cannabis companies often pay TDR to produce and distribute investor-facing content about them, and those arrangements often involve cash and, in some cases, shares.

For example, TDR disclosed a 12-month agreement with MariMed for $7,500 per month, or $90,000 for the year, for its media and content services.

Also, Awakn Life Sciences compensated TDR with 125,000 common shares for a four-month engagement.

That doesn’t mean their coverage is always wrong or that the information isn’t useful. It does mean you need to know who is paying them when you see a bullish piece about a company.

TDR may be useful for finding information, interviews, and industry perspectives, but don’t treat their analysis as completely independent. It’s not. Just listen to blowhard Marc Cohodes, MSOS’ Dan Ahrens, and Brady Cobb.

If TDR is being paid by a company they’re covering, verify the underlying facts independently.

Note that TDR is near the bottom of reputable journalistic information or media. The POW Group likely ranks (pun intended) at the very bottom.

SEC filings/company filings → government documents →
company earnings calls →
major mainstream financial media → social media (TDR and The POW Group)

The good news is that as the cannabis industry gains more traction, coverage will shift to more mainstream and reputable sources.

. . . it sees value in:

°international/medical cannabis
°recreational
°European infrastructure
°scale
°EU-GMP
°expertise
°IP
°brands
°distribution networks
°licenses
°relationships
°synergies
°strategic positioning
°earlier mover advantage
°diversification

Who else is strategically valuable at today’s depressed valuations?

Tilray is an obvious name because it has a large international cannabis platform plus beverages, beer, distribution and consumer brands.

And yes, those of us who’ve continued to buy at recent near ATLs are excited.

I’m asking because it’s been mentioned that Trulieve will do it again August 18th and there is no proof I could find.

Also, just because a cannabis company rings the opening or closing bell doesn’t mean the stock will move.

We need to stop bullshitting and hyping stocks on minor news and other speculative stories.

Bullish Tilray Brands, but basing it on actual performance and actual regulations.

I’m voting out anyone that sells or disposes shares other than for tax reasons. Persofsky and Clanachan sold some shares [for tax reasons, which is normal]. <-revised

Hopkinson did not sell any RSU.

Haven’t seen Simon’s or Merton’s yet. Both have never sold shares on open market.

Anyone selling for non-tax reasons will receive a no vote from me.

WONDER IF THOSE SELLING ARE LEAVING THE BOD VOLUNTARILY/UNVOLUNTARILY. <-Revised (I was wrong reading Form 4 as all dispositions submitted showed selling only for tax reasons which is normal)

Anyone with more knowledge about RSU’s - please respond.

Might be as smart a promotion as the BrewDog and FIFA World Cup promotion.

Also with medical. Maybe Breckenridge and popsicle inspired flavors.

Southern Glazer’s is the largest beverage alcohol distributor in North America.

They were mentioned in earnings call today.

Watch to see if the relationships expands, particularly with infused beverages.

There’s been plenty of speculation, both bullish and bearish, surrounding Tilray Brands.

The reality is that it’s extremely difficult to gain an investing “edge” with this company. I can’t even find out much about corporate culture or what it’s like to work with the executive team there.

Tilray has consistently demonstrated that it takes confidentiality and financial reporting seriously, keeping its earnings results close to the vest until they’re officially released.

In my view, that’s a positive attribute. It reflects disciplined management and respect for the integrity of the reporting process.

There’s also been a great deal of discussion about the company’s potential, its portfolio of brands, and future opportunities.

Ultimately, though, potential needs to translate into execution. The value of those brands and opportunities has to be demonstrated through tangible results, operational performance, and consistent financial progress, not just speculation.

We can debate and speculate on social media 24/7, but none of us truly knows what tomorrow’s earnings call will bring.

I’m bullish and looking forward to the results.

To those of us engaged on this subreddit, let’s be “serious people” and take the information and discussions here with a critical eye. It’s just social media.

The reality is reading filings, understanding the industry, diversifying & rebalancing investments, and having a longer term outlook.

Two important future dates.